Birgit Girshick compensation by year
CHARLES RIVER LABORATORIES INTERNATIONAL Summary Compensation Table · all 2 fiscal years held| Component | FY2023 | FY2025 |
|---|---|---|
| Salary | $704,811 | $760,960 |
| Bonus | $0 | $0 |
| Stock awards | $2,964,471 | $4,123,624 |
| Option awards | $744,677 | $0 |
| Non-equity incentive | $442,830 | $861,800 |
| Pension and deferred compensation | $0 | $0 |
| All other | $132,882 | $152,008 |
| Total | $4,989,672 | $5,898,392 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: CHARLES RIVER LABORATORIES INTERNATIONAL, INC. DEF 14A filed March 31, 2026, accession 0001104659-26-037367, and prior-year filings. Open the filing on EDGAR.
Equity holdings
unvested awards at FY2025 year-end| Type | Unvested units | Value at year-end | Exercise price |
|---|---|---|---|
| PSU | 48,598 | $9,897,469 | — |
| RSU | 17,638 | $3,592,155 | — |
| Option | 3,659 | — | $337.99 |
| Option | 6,500 | — | $179.66 |
| Option | 4,573 | — | $194.12 |
| Option | 6,542 | — | $208.44 |
| Option | 1,659 | — | $244.41 |
Per the Outstanding Equity Awards at Fiscal Year-End table in CHARLES RIVER LABORATORIES INTERNATIONAL, INC.'s FY2025 proxy; value at the fiscal year-end close, as the company printed it.
Insider transactions since the last proxy
11 Form 4 lines since the FY2025 proxy (filed March 31, 2026)current to 2026-09-24 · updated nightly
| Date | Transaction | Plan | Shares | Price | Held after |
|---|---|---|---|---|---|
| 2026-08-19 | Gift | — | 528 | $0.00 | 35,485 |
| 2026-08-11 | Exercise or conversion derivative | 10b5-1 | 6,500 | $0.00 | 0 |
| 2026-08-11 | Exercise or conversion | 10b5-1 | 6,500 | $179.66 | 42,513 |
| 2026-08-11 | Sale | 10b5-1 | 6,500 | $279.90 | 36,013 |
| 2026-06-05 | Gift | — | 3,386 | $0.00 | 43,803 |
| 2026-06-05 | Gift | — | 3,386 | $0.00 | 36,013 |
| 2026-05-31 | Tax withholding | — | 378 | $180.71 | 39,399 |
| 2026-05-30 | Tax withholding | — | 1,204 | $180.71 | 39,777 |
The 8 most recent of 11 lines, each as reported on the Form 4. "10b5-1" marks a trade the filing reports under a pre-arranged trading plan. View every Form 4 filing on EDGAR →
Change-in-control & termination
estimated payments CHARLES RIVER LABORATORIES INTERNATIONAL discloses, by trigger · FY2025| Trigger | Cash severance | Accelerated equity | Benefits continuation | Total as disclosed |
|---|---|---|---|---|
| Voluntary resignation | — | — | — | $1,428,918 |
| Involuntary for cause | — | — | — | $1,428,918 |
| Disability | — | $1,072,756 | — | $2,799,208 |
| Change in control and involuntary termination | $2,696,130 | $5,858,897 | $35,018 | $10,366,497 |
| Change in control, no termination | — | $5,858,897 | — | $7,585,349 |
| Retirement | — | — | — | $1,428,918 |
| Death | — | $2,603,177 | — | $4,329,629 |
| Involuntary termination without cause | $1,497,850 | — | $9,634 | $3,011,402 |
| Change in control and resignation for good reason | $2,696,130 | $5,858,897 | $35,018 | $10,366,497 |
Per the Potential Payments Upon Termination or Change in Control table in CHARLES RIVER LABORATORIES INTERNATIONAL, INC.'s FY2025 proxy. Estimates as the company printed them; a dash means it printed no figure.
CHARLES RIVER LABORATORIES INTERNATIONAL’s named executive officers, FY2025
as the company reported each| Named executive officer | Role | FY2025 total |
|---|---|---|
| James Foster | Chair, President and Chief Executive Officer | $15,435,220 |
| Birgit Girshick · this page | Corporate Executive Vice President, Chief Operating Officer | $5,898,392 |
| Joseph LaPlume | Corporate Executive Vice President, Corporate Development & Strategy | $3,513,345 |
| Victoria Creamer | Corporate Executive Vice President and Chief People Officer | $3,332,387 |
| Michael Knell | Interim Chief Financial Officer, Corporate Senior Vice President, and Chief Accounting Officer | $2,107,684 |
The full CHARLES RIVER LABORATORIES INTERNATIONAL compensation record
free company briefThis page is one person within CHARLES RIVER LABORATORIES INTERNATIONAL's record. The company brief lists every named executive, each linking to their own page.
Compensation, the day it’s disclosed
The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them. Or order CHARLES RIVER LABORATORIES INTERNATIONAL's full Executive Compensation Report with peer benchmarking.
How this record is built
Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are CHARLES RIVER LABORATORIES INTERNATIONAL's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.
Velarion Pro: every company page, peer tools and exports, one seat